• In late May 2026, Gilead Sciences reported positive Phase 3 data for Livdelzi in primary biliary cholangitis, secured accelerated FDA approval for Hepcludex as the first U.S. treatment for chronic hepatitis delta, and received a favorable European regulatory opinion expanding Trodelvy’s use in metastatic triple-negative breast cancer.
• Together, these liver and oncology milestones highlight Gilead’s growing presence in complex specialty diseases where few effective treatment options exist today.
• Next, we’ll explore how Hepcludex’s accelerated approval could influence Gilead’s existing investment narrative around growth, risk, and portfolio diversification.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Gilead Sciences Investment Narrative Recap

To own Gilead today, you need to believe its HIV cash flows can fund a broader, durable franchise in liver disease and oncology. The latest Livdelzi, Hepcludex and Trodelvy updates reinforce that diversification effort, but they do not change the near term focus on execution risk around new launches and ongoing policy and pricing pressure in HIV, which still anchors the investment debate.

Among the recent announcements, Hepcludex’s accelerated FDA approval for chronic hepatitis delta stands out most. It adds a first in class therapy in a serious, underserved liver disease, deepening Gilead’s liver portfolio alongside Livdelzi. How quickly physicians adopt Hepcludex and how payers treat pricing and access will be important real world tests of Gilead’s ability to turn its specialty pipeline into meaningful, diversified revenue.

Yet investors should also understand how increased reliance on new specialty launches could magnify the impact if any of them stumble on pricing or uptake...

Gilead Sciences’ narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected Gilead to reach about US$38.6 billion in revenue and US$12.3 billion in earnings by 2029, so this kind of liver and oncology news could either strengthen that bullish case or expose how dependent it is on everything going right.

Explore 6 other fair value estimates on Gilead Sciences - why the stock might be worth just $128.38!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 12 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.